BIO-TECHNE CORP shareholders Q3 2023

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q3 2023
NameSharesValueWeighting ↓
Quantbot Technologies LP 47,284$3,218,6220.22%
First Light Asset Management, LLC 32,889$2,238,7680.21%
MACQUARIE GROUP LTD 2,470,651$168,177,6590.21%
Johnson & White Wealth Management, LLC 3,412$2320.21%
Dynamic Technology Lab Private Ltd 29,303$1,9950.20%
SNYDER CAPITAL MANAGEMENT L P 126,832$8,633,4540.20%
Paradigm, Strategies in Wealth Management, LLC 4,373$297,6700.19%
Legacy Wealth Asset Management, LLC 7,436$506,1690.19%
ASHFORD CAPITAL MANAGEMENT INC 18,160$1,236,1510.18%
RMB Capital Management, LLC 76,220$5,188,2950.18%
Inspire Investing, LLC 20,031$1,363,5100.17%
Neo Ivy Capital Management 5,672$3860.17%
BEACON INVESTMENT ADVISORY SERVICES, INC. 49,283$3,354,6940.16%
Jump Financial, LLC 62,265$4,238,3790.16%
Bridgefront Capital, LLC 3,397$231,2340.16%
Sweet Financial Partners, LLC 8,880$604,4620.16%
Andra AP-fonden 39,900$2,715,9930.16%
Y-Intercept (Hong Kong) Ltd 23,986$1,632,7270.16%
Machina Capital S.A.S. 4,133$281,3330.16%
XTX Topco Ltd 12,970$882,8680.15%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q3 2023. To view BIO-TECHNE CORP's shareholder history, click here.